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Abstract 
We previously showed that mast cells are important in the initiation of ocular inflammation 
but the exact consequences of mast cell degranulation on ocular pathology have not been 
characterized. We induced mast cells depletion of their inflammatory mediators by the local 
sub-conjunctival injection of 48/80 drug. Initial degranulation of mast cells was observed in 
the choroid 15 min after the injection of 48/80, with degranulation continuing to increase up 
to 3-6 hrs after the injection. The signs of anterior segment clinical inflammation paralleled 
mast cell degranulation. Posterior segment imaging using optical coherence tomography 
showed increased choroidal thickness and serous retinal detachments, which were confirmed 
by histological analysis. The infiltration of polymorphonuclear cells was associated with 
increased ocular media levels of TNF- at 1 and 3 hrs, followed by CXCL1, IL-6, IL-5, CCL-
2 at 6 and 24 hrs, and IL-1 at 24 hrs. Analysis of levels of VEGF and IL-18 at all time 
intervals showed an opposite evolution of VEGF as compared to IL-18 levels suggesting that 
they could control each other production. These findings suggest that the local degranulation 
of ocular mast cells provokes acute ocular inflammation, increased choroidal vascular 
permeability and serous retinal detachments. The involvement of mast cells in retinal diseases 
should be investigated and the pharmacological inhibition of mast cells degranulation 
considered as a potential intervention target.
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Introduction 
 
Mast cells have been detected in the lids, conjunctiva, the uveal tract (iris, ciliary body and 
choroid) of several different species.
1,2,3,4,
 In humans and rats, mast cells are abundant in the 
anterior and posterior uvea but absent in the retina.
5
 These cells are understood to originate 
from hematopoietic progenitors and following migration to vascularized tissues to mature 
locally.
6
 Mast cells are activated by danger signals which have a specific pathogen-associated 
molecular pattern; exogenous signals such as lipopolysaccharide (LPS), zymosan, and 
peptodiglycan
7
 and endogenous signals such as Interleukin-33 (IL-33), a cytokine of the IL-1 
family have been shown to cause activation.
8
 It is understood that the fusion of secretory 
granules with the plasma membrane results in the quick release of a number of cytokines and 
vasoactive amines such as histamine, contributing to the recruitment of neutrophils.
9
 As such, 
mast cells initiate immune responses, in cases such as allergic disorders and immune 
responses to pathogens.
6,10,11
 
In the eye, degranulation of choroidal mast cells has been shown to contribute to the early 
onset of Experimental Autoimmune Uveoretinitis (EAU)
4,12
 and of Endotoxin Induced Uveitis 
(EIU).
13,14
 On the other hand, the depletion of mast cells from their inflammatory mediators 
with the compound 48/80 was shown to prevent EAU development.
12
 Moreover, topical 
ocular medications designed to block mast cell degranulation have been reported to decrease 
the clinical severity of the disease during EAU.
12
 Serous retinal detachments (SRD) which are 
almost always observed during EAU are often observed in eyes with ocular inflammatory 
disorders such as Vogt-Koyanagi-Harada disease.
15
 However there may be multiple 
mechanisms leading to SRD, as they also are present in other ocular disorders such as central 
serous chorioretinopathy and wet Age related Macular Degeneration (AMD).
16
 In AMD for 
example, genetic studies have demonstrated that complement alternative pathway activation is 
associated with increased prevalence of the disease.
17,18,19
 Deposits of C5a, a potent mast cells 
degranulating component,
20
 have been detected in the choroid and retinal pigment epithelium 
of eyes with AMD,
21
 suggesting that mast cells may be a complement pathway effector in 
AMD pathogenesis. 
 In order to clarify the direct role of mast cells in ocular pathology, we examined the effects of 
specific ocular mast cells degranulation in rats by the local unilateral subconjunctival 
injection of the synthetic compound 48/80. 
Materials and Methods 
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Animals 
Adult female Lewis rats (6–8 weeks old, Janvier, Le Genest-Saint-Isle, France) were used in 
this study. Animals were housed in a 12-hrs light and 12-hrs dark cycle and fed water and 
dried ration ad libitum. Experimental procedures were submitted and approved by the ethic 
committee of Paris Descartes University (number: Ce5/2012/122). The care and use of the 
animals was in compliance with ARVO statement for the Use of Animals in Ophthalmic and 
Vision Research. Accreditation N° of the laboratory: B 75 06 02. 
 
Injections 
Anesthesia of rats was performed by intraperitoneal injection of pentobarbital (25 mg/kg 
Nembutal; Abbot, Saint-Remy sur Avre, France). One drop of 1% tetracaine  (Sigma-Aldrich, 
Saint Quentin Fallavier, France) was instilled for local anesthesia.  
-Subconjunctival administration of compound 48/80: One subconjunctival injection of 
solution of compound 48/80
12,14
 (Sigma-Aldrich) (120 g of 48/80 in 100 L of sterile 
pyrogen-free saline), was performed in the right eye in the temporal site of the conjunctiva as 
previously described
12
 using 1 mL syringes with 30G needle. Left eye was not injected.  
-Subconjunctival administration of NaCl: Control rats were injected subconjunctivally with 
vehicle (NaCl 0.9%).  
-Subconjunctival injection of disodium cromoglycate: Disodium cromoglycate (DSCG, 
cromolyn sodium salt, Sigma-Aldrich) blocks the release of mediators from mast cells.
6
 One 
subconjunctival injection of DSCG (2 mg DSCG/rat weighing 200 g dissolved in 100 L 
saline) was administered at the nasal site 15 min before the subconjunctival administration of 
compound 48/80 performed at the temporal site.  
 
In vivo investigations  
Clinical examination 
Eyes were examined with a biomicroscope (slit lamp) at regular time intervals in 48/80-
injected eyes, in contralateral non-injected eyes and in eyes from the group injected with 
DSCG i.e. 10-30 min, 1, 2, 3, 4, 5, 7, 24 hrs after 48/80 subconjunctival injection. At each 
time point, the conjunctiva, lens, iris and pupil and the anterior chamber were observed. 
Pupillary dilation was obtained after administration of a drop of mydriaticum (Thea, Clermont 
Ferrand, France). The severity of the reaction to the subconjunctival injection of 48/80 took 
into account each ocular inflammatory sign: -conjunctival edema, -vasodilation of iris vessels, 
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myosis, - fibrin exudate, - hypopion, -iris haemorrhages, - synechiae. Presence of each sign 
was encoded as 1, absence as 0, the severity of the response was evaluated in each eye by the 
sum of the pathological signs/eye. Alteration of the lens transparency (cataract) was also 
evaluated. 
 
Optical Coherence Tomography (OCT) 
The assessment of rat retina and choroid was performed on anesthetized animals using 
spectral domain optical coherence tomography (SD-OCT, Spectralis™ device, Heidelberg, 
Germany) adapted for small animal eyes.
22
 Pupils were dilated with 5% tropicamide drops. 
Scans were taken in the same rats prior to treatment and at 1, 3, 6 and 24 hrs after 48/80 
subconjunctival injection. Each two-dimensional B-scan recorded at 30° field-of-view 
consisted of 1536 A-scans with an optical resolution reaching 3.5 μm and the enhanced depth 
imaging option (EDI) was used to evaluate the choroidal thickness.
23
  
 
Ex vivo investigations 
 
Experimental groups of rat eyes were as follows: 48/80-injected eyes, contralateral non-
injected eyes and NaCl-injected eyes, enucleated at 4 time points after 48/80 injection at 
namely 1 hr, 3 hrs, 6 hrs and 24 hrs. Number of experimental eyes are indicated in figure 
legends. 
 
Flat-mounted preparations of the choroid (as previously described
4
) for staining and 
quantification of choroidal mast cells degranulation  
-Choroidal mast cell staining: The retina was removed and the choroid and the adhering 
sclera were placed into a fixative solution containing: anhydrous acetic acid: 95% ethanol : 
40% formalin : distilled water = 1 : 15 : 6 : 30.  After 60 min, the choroid was detached from 
the underlying sclera, washed in 95% ethanol and stained for 40 min in 0.25% solution of 
toluidine blue in 70% ethanol acidified with HCL (pH 2.4). Choroids were dehydrated and 
mounted in Eukitt (VWR, Fontenay-sous-Bois, France). Under these staining conditions, only 
mast cell granules were stained.  
-Choroidal mast cell quantification: Choroidal mast cells were then counted using an ocular 
grid at the magnification of x250, 200 to 1000 mast cells were assessed on 10 to 20 grid areas 
for each choroid. Mast cells were considered as degranulated when showing an irregular 
shape, altered cell membrane and extracellular granules.  
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The density of degranulated and non-degranulated mast cells (mean cells ± SEM per mm
2 
of 
choroid) were calculated at different time intervals post-injection in 48/80-injected eyes and 
in contralateral non-injected eyes.  
 
Immunohistochemistry on flat mounts of RPE/choroid  
Enucleated eyes were fixed in 4% paraformaldehyde (PFA) for 15 min at room temperature 
and sectioned at the limbus; the anterior segment and the retina were discarded. Flat mounts 
of RPE/choroids were fixed for additional 15 min in acetone at −20°C. Specimens were 
incubated overnight at 4°C with primary antibody diluted in PBS and 0.1% Triton X-100. 
Primary antibody used was: rabbit polyclonal anti-occludin (dilution 1 : 200; Zymed, San 
Francisco, CA, USA). Occludin is an integral plasma-membrane protein located at the tight 
junctions and is involved in cell adhesion and permeability.
24
 The corresponding Alexa 
secondary antibody (Invitrogen life technology Carlsbad) was used to reveal the primary 
antibody and sections were counterstained with 4', 6-diamino-2-phenylindol (DAPI) (Sigma-
Aldrich).  Sections and flat-mounts were viewed with a fluorescence microscope (Olympus 
BX51) and confocal microscope (LSM 510 laser scanning microscope Zeiss, Carl Zeiss, Le 
Pecq, France). Images were exported to Photoshop software for preparation of final images. 
Staining that omitted the primary antibody served as negative control.  
 
Histological sections for the assessment of ocular pathology and choroidal thickness  
Eyes were fixed in 0.5% glutaraldehyde / 4% paraformaldehyde (PFA) for 2 hrs, dehydrated 
in a graded alcohol series (50%, 70%, 95% and 100%) and embedded in epoxy resin, 5 m 
section were cut and stained with toluidine blue. The morphology and pathological 
modifications of ocular tissues were examined under a light microscope (DM5500B, Leica, 
Nanterre, France). 
Choroidal thickness was measured (ImageJ) on photographs taken on historesin sections from 
the optic nerve to the ciliary body. Each measurement was taken at 300 m on each side of 
the optic nerve
25
 of 48/80-injected eyes, contralateral non-injected eyes and NaCl-injected 
eyes. 
 
TUNEL assay  
Enucleated eyes were snap frozen in Tissue-Tek OCT-compound (Bayer Diagnostics, 
Puteaux, France). Cryostat sections (10µm) were fixed in 4% PFA for 15 min and 
permeabilized with 0.1% Triton X-100 for 30 min. Apoptosis of cells was assessed on 
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cryostat sections with a terminal deoxynucleotidyl transferase dUTP nick-end labeling 
(TUNEL) kit (Roche, Indianapolis, IN) in strict accordance with the manufacturer’s 
instructions. 
 
Cytokine and chemokine analysis in ocular fluids by multiplex ELISA  
Aqueous humor and vitreous body (ocular media) from each eye were collected, pooled and 
centrifuged allowing separation of ocular fluids from ocular infiltrating cells. According to 
the manufacturer’s instructions, multiplex ELISA assay (Milliplex Map Kit, Saint-Quentin en 
Yvelines, France) was performed on rat ocular fluids (xMAP technology assay) as follows: 
the following inflammatory mediators were measured: chemokines: MCP-1/CCL2, MIP1-
α/CCL3, RANTES/CCL5, IP10/CXCL10 (IFN-inducible protein-10) and GRO/KC/CXCL1/ 
CINC; inflammatory mediators: IL-1β, IL-18, TNF-α, IL-2, IFN-γ, IL-4, IL-5, IL-6, IL-10, 
IL-13, IL-17 and VEGF (Clinisciences, Montrouge, France). Detection thresholds were 
estimated around 1 to 10pg/mL. The nomenclature CCL2 and CXCL1 was used throughout 
the study.  
 
Statistics 
Data were expressed as means ± SD. Statistical analysis was made using the Graphpad 
Prism5 program (Graphpad Software, San Diego, CA, USA). A Mann Whitney test was used 
for comparison between two groups and comparisons more than two groups were performed 
using one-way ANOVA test followed by Bonferroni’s comparison, significance was 
investigated at the 5% level for all test types. 
 
Results 
 
Subconjunctival injection of 48/80 induces clinical ocular inflammation  
Biomicroscope (slit lamp) examination was performed at different time intervals after 48/80 
or saline injection. Unilateral clinical signs of ocular inflammation were observed (Fig. 1A, 
B). At 10 min post 48/80 injection, conjunctival edema and intense vasodilation of iris vessels 
were observed (Fig. 1A). From 3 hrs to 24 hrs, hazy cornea, fibrin deposit, hypopion (small 
amount of pus or collection of white cells) and synechiae (adherence of the iris to the lens) 
were observed in the anterior chamber of the eyes. Punctate hemorrhages in the iris were 
occasionally found (Fig. 1A). In 17 out of 25 rats (68%) a transitory cataract was observed 
from 1hr post 48/80 injection, that persisted until the 3
rd
-6
th
 hrs and then faded. No clinical 
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sign of inflammation could be observed in contralateral non-injected eyes and in rats injected 
with NaCl (not shown).   
As shown in Fig. 1B, whereas no pathological signs were detected in the left eyes not injected 
with 48/80, all right eyes injected with 48/80 showed significant signs of anterior segment 
inflammation from 15-30 min reaching a peak at 1-2 hrs and significantly slowly decreasing 
between 3 and 24 hrs post injection.   
In the eyes where mast cell mediator release inhibitor DSCG was injected 15 min prior to 
48/80, no clinical signs of inflammation were observed (not shown). 
 
Morphological modifications and quantification of mast cells in choroid flat mounts.  
The morphology of choroidal mast cells was analysed using flat mounts preparations (Fig. 2). 
Mast cells are regularly located around large choroidal vessels. In left non-injected eyes (Fig 2 
A-C, inset) and NaCl-injected eyes (not shown), mast cells displayed an intact morphology at 
all-time points with high number of condensed intracellular granules intensively stained with 
toluidine blue in the cytoplasm. In contrast, as early as 15 min after 48/80 injection occasional 
degranulated mast cells were seen (not shown). At 1 hr after 48/80 injection, the number of 
degranulated mast cells importantly increased with granules extruded from the cytoplasm 
(Fig. 2 D, inserts). At 3 hrs, mast cells showed reduced density of cytoplasmic granules and 
an extensive and massive degranulation in all mast cells present in the choroid (Fig. 2 E, 
insert). At 24 hrs, all mast cell still presented an abnormal shape but the granules were again 
stained intensively (Fig. 2 F, insert). 
Choroidal mast cells density was calculated on flat mounted preparations. Variations in the 
number of choroidal mast cells (degranulated or intact) at 1h and 3h are shown in Fig. 2 G, H. 
Compared to contralateral non-injected eyes, the number of degranulated mast cells was 
significantly higher at 1 hr and 3 hrs in 48/80 injected eyes (Fig. 2 G). Correlatively, 
significantly lower number of non-degranulated mast cells was found in 48/80-injected eyes 
compared to non-injected eyes (Fig. 2 H). 
 
Ocular pathology induced by mast cells degranulation 
Pathological modifications of ocular tissues were evaluated in historesin sections. In left non-
injected eyes, mast cells showed a normal resting shape (Fig. 3, A, C), at the vicinity of 
vessels at the limbus of the cornea (Fig. 3 A, insert) and also in the choroid (Fig. 3 C, insert). 
In the right 48/80-injected eyes, at 1 and 3 hrs, degranulated mast cells were observed in the 
vicinity of vessels at the limbus of the cornea (Fig. 3 D, insert) and in the conjunctiva (Fig. 3 
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E, insert). In these eyes, mast cell degranulation in the anterior segment was associated with 
intense infiltration of PMNs (Fig. 3 F, insert, arrowhead) and macrophages (Fig. 3 F, insert, 
arrow) at 3 hrs to persist up to 24 hrs, and with alterations of corneal endothelial cells (Fig. 3 
F, asterisk). In the posterior segment, mast cell degranulation was associated with fibrin 
exudate above the RPE in the subretinal space (Fig. 3 G, arrow) together with choroidal 
vessel dilation (Fig. 3 G, asterisk). Moreover, exudative retinal detachments appeared in the 
same locations as moderate to extensive ruptures of the RPE barrier and important retinal 
folds (Fig. 3 G and 3 H).  
Starting at 1 hr (Fig. 3 G) after 48/80 injection to be very important at 3 hrs-24 hrs (Fig. 3 H), 
alterations of the retinal nuclear cell layers with picnotic aspects of the nuclei of 
photoreceptors and bipolar cells visible at the level of the retinal detachment. At 24 hrs, 
detachments and large destructions of the retina were observed (Fig. 3 H). Numerous 
TUNEL-positive nuclei were detected at 3 hrs (Fig 3 J) and at 24 hrs (Fig. 3 K), in the three 
nuclear cell layers, aspects consistent with the pathological aspect of retinal cells shown in 
historesin section (Figure 3 H). 
 
OCT examination of posterior segment of the eye  
One hour post 48/80 injection, the retina presented undulations, the apex of which were hyper 
reflective (Fig. 4 A, B, arrows). From 3 hrs to 24 hrs after 48/80 subconjunctival injection, 
larger and multiple retinal serous detachments were observed (Fig. 4 D, E, G, F) with pockets 
of subretinal fluid (Fig. 4 D, E, G, F, stars). Detachments of the neuroretina, due to subretinal 
accumulation of material were observed on histological section (Fig. 4 C, arrow). Edema was 
located in the retinal nuclear cell layers (Fig. 4 C, F, arrowheads). An increase of the  
choroidal thickness (Fig. 4 H, I, arrowheads) was observed related to dilation of the 
choriocapillaris (Fig 4 I star) and large choroidal vessels (Fig 4 I asterisk). No pathological 
changes were observed in contralateral non-injected eyes. 
 
 
Increase of choroidal thickness in 48/80-injected eyes  
At 1-3 hrs, compared to choroidal thickness in the left non-injected eyes and in NaCl-injected 
eyes, a significant and localized increase of choroidal thickness was detected in right 48/80- 
injected eyes (Fig. 5 A, B). At 6 -24 hrs, the choroidal thickness increase extended also to the 
periphery and all over the choroid surface (Fig. 5 C, D).  
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RPE barrier breakdown induced by mast cell degranulation 
RPE flat mount were used to visualize the RPE cells junctions at 1 hr after 48/80 injection. In 
NaCl and contralateral non-injected eyes, occludin labelled a regular hexagonal membrane of 
the RPE cells (Fig. 4 A). In 48/80-injected eyes, an abnormal shape in some RPE cells with 
irregular occludin labelling (Fig. 4 B, arrowhead) was observed. In particular RPE cells 
defects (Fig. 4 B, C, stars) and localized enlargement of intercellular space (Fig. 6 D, 
arrowhead) were present throughout.  
Close examination of historesin sections, showed a regular interface between the RPE cell 
monolayer and Bruch’s membrane in contralateral non-injected eyes (Fig. 4 E, arrows), 
whereas in 48/80-injected-eyes, large alterations of the RPE were detected at all time points, 
in locations adjacent to the choriocapillaris (Fig. 6 F asterisk). RPE cells detached from the 
basal membrane and migrated, in either isolated or as large sheets of RPE, into the subretinal 
space (Fig. 4G, arrowhead). These round, binuclearly detached cells, allowed the positive 
identification of the RPE cells (Fig. 4 G).  
 
Effect of mast cells degranulation by compound 48/80 on ocular cytokine and chemokine 
concentrations in ocular fluids  
Multiplex ELISA analysis showed that the level of several inflammatory mediators was 
significantly higher in 48/80-injected eyes compared to control NaCl-injected eyes (Fig. 7). 
As early as 1 hr after 48/80 injection, TNF- was significantly increased as compared to 
NaCl-injected eyes (Fig. 7 A). This increase persisted at 3 hrs, but not at 6 hrs. A significantly 
increased level of IL-5 was observed at 3 hrs, 6 hrs and 24 hrs (Fig. 7 B), together with 
significantly increased levels of IL-6 and CCL-2 at 6 hrs and 24 hrs (Fig. 7 C, D). 
Furthermore a significant increase of IL-1, CXCL-1 and IL-18 was observed at 24 hrs (Fig. 
7 E, F, G) while significant decrease of VEGF occurred at this time (Fig. 7 I). Levels of IL-18 
(Fig. 7 H) and VEGF (Fig. 7 J) mirrored each other suggesting co-regulation. The cytokine 
levels in the contralateral non-injected eyes were consistent with levels found in NaCl eyes.  
 
Discussion  
A local subconjunctival injection of 48/80 (which specifically induces mast cells 
degranulation), was used to analyse the sequence of events occurring in the eye after mast cell 
degranulation. It showed a strong clinical and morphological inflammatory reaction detected 
in both posterior and the anterior segments of the eye. But the acute mast cell degranulation in 
ocular tissues also induced remarkable posterior segment pathology, beginning with choroidal 
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thickening and outer retinal barrier breakdown that resulted in serous retinal detachments 
(SRD). These SRD are similar to those observed in some forms of acute posterior uveitis such 
as Behçet
26
 and Vogt-Koyanagi-Harada
15
 diseases, indicating that these eyes may share some 
pathogenic mechanisms. Since mast cells mature locally in the vicinity of vascularized 
tissues, the site of their final residence,
6
 a local degranulation of mast cell in one eye is not 
expected to induce pathology in the contralateral eye, which was confirmed by unilateral 
clinical signs and the lack of morphological changes in the contralateral eye.  
Interestingly, a second subconjunctival injection of 48/80 performed 7 days after the 
first one, induced the same pathological signs (not shown). In human pathology, one could 
expect that if the stimulus persists, successive degranulations could occur, leading to chronic 
signs.In 48/80-injected eyes, mast cell degranulation elicited a complex sequence of 
morphological changes. The early blood-aqueous barrier breakdown, coincided with a 
transitory cataract, which dissipated spontaneously by 6 hrs post 48/80 injection. Such 
transitory cataract has not been observed in other acute models of intraocular inflammation, 
suggesting  that mediators specifically released by mast cell degranulation induced metabolic 
alterations of the lens epithelium and /or disruption of epithelial tight-junctions, altering the 
lens homeostasis and inducing lens opacity.
27
 In addition to the anterior segment 
inflammation induced by 48/80, choroidal mast cells degranulation provoked posterior 
segment pathology. As early as one hour post 48/80 injection, serous retinal detachments 
(SRDs) were observed. These SRDs increased in severity (area and height) with time up to 24 
hrs as observed with in vivo OCT imaging. At this time point, anterior segment inflammation 
was observed to lessen. On histology, choroidal thickening and choroidal vessels dilation 
were observed very quickly post 48/80 injection, followed by RPE barrier disruption and 
SRD, which were associated with numerous RPE cells defects. The notably short time from 
mast cells degranulation until RPE barrier breakdown suggests direct junction destabilization 
by the released mediators. Histamine has been shown to induce tight-junctions opening in 
corneal endothelial cells
28
 and in retinal vascular endothelium.
29
 Histamine administered 
intravenously also increased choroidal blood flow as evaluated by laser doppler in humans.
30
 
But whether histamine induces direct effects on RPE tight-junctions, or whether it is a 
consequence of other inflammatory mediators has not yet been explored. In rat EAU, we have 
shown that the degranulation of choroidal mast cells peaked before the first pathologic signs 
were observed, suggesting the role of early mast cell degranulation as a trigger of ocular 
edema, inflammation and lesions.
4,12
 Other inflammatory mediators released by mast cells, 
together with ocular infiltrating cells, may also participate to induce tissue lesions.
4,13,14
  
 12 
Mast cells have a large catalogue of cell surface receptors, such as IgE receptors, complement 
component receptors, and various Toll like receptors. Moreover, mast cells respond to a large 
variety of stimuli
31
 and induce the synthesis of TNF- and IL-6.32 In the present study, TNF-
, was the first cytokine to be up regulated in the eye (1 hr after 48/80 injection), followed by 
IL-6 (6 hrs), confirming that TNF- could be an inducer of IL-6 release during ocular 
inflammation.
33
 It is understood that TNF- can contribute to the outer retinal barrier 
breakdown, as rat RPE cell monoculture co-incubated with TNF- together with LPS+IFN- 
altered RPE tight junctions with abnormal distribution of ZO-1.
34
 Experimental ocular 
inflammation is characterized by the breakdown of blood-ocular barriers allowing 
inflammatory cells, including macrophages and polymorphonuclear leukocytes (PMNs), to 
invade the ocular tissues (Protein Kinase C_ (PKC_) Regulates Ocular 
Inflammation and Apoptosis in Endotoxin-Induced Uveitis (EIU) Signaling Molecules 
Involved in EIU Resolution by PKC_Inhibitor and Interleukin-13. The American Journal of 
Pathology, Vol. 170, No. 4, April 2007).   Mast cells also modulate neutrophil influx and 
recruit neutrophils through TNF- release.35 The injection of HrIL-6 (Human recombinant 
IL-6) into the vitreous has been reported to induce an accumulation of neutrophils in the 
anterior and posterior segments of the eye.
36
 Further, in the present situation, the rat 
chemokine CXCL-1 (a neutrophil chemoattractant) was also significantly increased and 
responsible, together with TNF- and IL-6, for the neutrophils infiltration of the anterior 
chamber. Combined, these different mediators, successively produced, created the structure to 
allow the neutrophil infiltration observed after 48/80 injection in study eyes. Further, IL-18, a 
potent neutrophil-activating factor,
37,38
 was augmented after 48/80 injection with an opposite 
regulation of the levels of VEGF. At 24 hrs, significantly higher levels of IL-18 and lower 
levels of VEGF were observed in 48/80-injected rats as compared to contralateral eyes. The 
exact role of IL-18 in the eye is still unclear
39
 but VEGF and IL-18 were shown to suppress 
each other’s production.40 In a mouse model of neovascularization,41 IL-18 inhibited new 
vessel formation but promoted damages to the RPE that mimics aspects of the dry form of 
AMD.
42
 Alteration of RPE cells after mast cell degranulation could thus be at least in part 
related to IL-18 increase.  
This study shows for the first time that mast cells degranulation induces choroidal, RPE and 
retinal pathology resulting in serous retinal detachment, a sign common to various retinal 
diseases. Development of spectral-domain OCT using enhanced depth imaging module has 
allowed to identify a wide spectrum of chorioretinal diseases associated with pachychoroid 
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(choroidal thickening) such as central serous chorioretinopathy and polypoidal choroidal 
vasculopathy.
43
 Whether mast cell degranulation could be involved in such conditions should 
be explored. The fact that mast cells progressively reconstitute their granules evokes that if 
the stimulus persists, successive degranulations could lead to chronic barriers breakdown and 
sub-retinal fluid accumulation. In AMD, complement activation leads to C5a accumulation in 
the choroid, which could also induce mast cells degranulation
21
 contributing to exudative 
complications.  
In conclusion, since factors that trigger or result from mast cell degranulation have been 
identified in the pathogenesis of many “a priori” non-inflammatory diseases, including AMD, 
we suggest that mast cell degranulation could be an important factor in chronic ocular 
diseases as well as in acute ocular inflammation. Pharmacological inhibition of mast cell 
degranulation by inhibiting the release of inflammatory mediators could have an important 
therapeutic potential on retinal diseases associated with choroidal enlargement and/or serous 
retinal detachments. 
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Figure legends 
 
Figure 1. Clinical examination and grading of the pathological signs in the anterior 
segment of the eye after subconjunctival injection of 48/80. 
A. Slit lamp photographs were obtained from rats injected in the conjunctiva with 48/80. The 
eyes were observed from 10 min up to 7 hrs after injection. Edema of the conjunctiva was 
detected from 10 min after 48/80 injection (arrow). A cataract was observed in 17 out of 25 
eyes (68%), from 1 hr (asterisk) to diminish progressively up to 7 hrs. At 7 hrs in this eye, 
haemorrhages were observed in the iris (arrow) and in the conjunctiva (arrowhead).    
Original magnification: X 7; C : conjunctiva; i : iris ; co : cornea; 
n = 7 rats injected with 48/80  
n = 25 rats for observation of cataract in the right eyes  
 
 
B. Graph showing the clinical grading of rats injected with 48/80 in the conjunctiva of right 
eyes and non-injected in the controlateral left eyes and observed at the slit lamp from 15-30 
min to 24 hrs. Clinical signs developed from 15-30 min and peaked at 1hr-2hrs, to decrease 
from 3hrs. The intensity of clinical signs, compared to pic levels found at 1-2 hrs, significantly 
decreased at 3, 4, 5, 7 hrs and 24 hrs. Non-injected left eyes did not show any clinical 
abnormalities. n = 6 rats injected with 48/80 in the right eyes and not injected in left eyes 
*P<0.5; *** P<0.001,  
 
Figure 2  
A-H: Morphological alterations of mast cells in flat mounts of the choroid at different 
time points after subconjunctival injection of 48/80.  
At all time intervals in the left non-injected eye (A-C and insert), numerous normal mast cells 
were detected along choroidal vessels. In contrast, in the right 48/80-injected eyes, mast 
degranulation was visible at all time intervals tested as mast cell granules dispersed in the 
surrounding tissue (D-F). The intensity and number of degranulated mast cells increased with 
time, detectable in numerous mast cells at 1 hr (D) (insert) and to be maximum at 3 hrs (E) 
(insert). Extensively degranulated cells were visible with exocytosis of granules (D-E). At 24 
hrs (F), all mast cells presented an abnormal shape with dispersed granules intensively stained 
in blue with toluidine blue. 
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Photomicrographs were obtained from one eye/time point and are representative of similar 
flat mounts stained from 3 rats/time point. 
Scale bar: 30 m, insert X3 
G, H: Counting of choroidal mast cells  
G. The number of degranulated mast cells was significantly increased at 1 hr and 3 hrs in 
48/80-injected eyes compared to non-injected eyes. Low number of degranulated mast cells 
was detected at all time points in non-injected eyes.  
H. Correlatively, a significant decrease of the number of non-degranulated mast cells in 
48/80-injected eyes was detected at 1 hr and 3 hrs compared to non-injected eyes. High 
number of non-degranulated mast cells was detected at all time points in non-injected eyes. 
Data are means ± SEM, n = 3 rats per condition, * p<0.05.  
 
Figure 3: Pathological effects of mast cell degranulation in ocular tissues.  
Historesin sections of left non-injected eyes and right 48/80-injected eyes between 1 hr and 3 
hrs-24 hrs after 48/80 injection (A-H).  
In the left non-injected eyes (A, C) normal mast cells (inserts) were observed in the vicinity of 
vessels at the limbus of the cornea (A) and near choroidal vessels (C). Normal aspect of the 
ocular structures: cornea with endothelial cells regularly distributed (asterisk) (B), normal 
retina (C) and choriocapillaris (C, asterisk).  
In contrast, in the right 48/80-injected eyes (D-H), at 1-3 hrs, degranulated mast cells were 
observed in the vicinity of ocular vessels at the limbus of the cornea (D, insert), in the 
conjunctiva (E). From 1-3 hrs to persist up to 24 hrs after 48/80 injection, an important 
infiltration of PMNs (F, insert, arrowhead) and macrophages (F, insert, arrow) was observed 
in the aqueous humor behind the vacuolated endothelium of the cornea (F, asterisk). 
Important dilation of the choriocapillaris was observed (G, asterisk) associated with focal 
retinal detachment (G). A mobilized RPE cell was present in the subretinal space (G, 
arrowhead). Starting at 1 hr (G) after 48/80 injection to be very important at 3 hrs-24 hrs (H), 
alterations of the retinal nuclear cell layers with picnotic aspects of the nuclei visible at the 
level of the retinal detachment (H, asterisk). Fibrin deposits were seen all along the RPE (G, 
arrow). At 24 hrs, large retinal tissue destruction was observed (H). 
Retinal sections were immunostained by TUNEL assay (green) and DAPI (blue) (I-K). 
Normal retina was observed in the left non-injected eye (I). In contrast apoptotic retinal cells 
(TUNEL-positive nuclei) were detected in the three nuclear cell layers of the retina at 3 hrs 
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after 48/80 injection (J) and at 24 hrs (K) that will lead to the extensive lesions of retinal cells 
shown in historesin section (H, asterisk).  
48/80-injected eyes: n= 3; contralateral non-injected eyes: n=3. 
Original magnification: scale bar: 30 m (insert X4) 
 
Figure 4. Serous retinal detachment and choroidal vessels dilation after subconjunctival 
injection of 48/80. 
Optical Coherence Tomography (OCT) (A, B, D, E, G, H) and corresponding historesin 
sections (C, F, I) at different time points after 48/80 injection. 
At 1 hr, undulations and hyperreflective areas were detected at the level of retinal pigmented 
epithelium (A, B, arrows) corresponding to small retinal detachments on histological sections 
(C, arrows). From 3 hrs to 24 hrs after injection of 48/80, retinal serous detachments were 
observed with presence of subretinal fluid underneath (D, E, F, G, stars). Edematous areas 
were detected in the retina (C, F, arrowheads). An important dilation was detected in the 
choriocapillaries (star) and choroidal vessels (asterisk) (I). 
At 1 hr: n = 6, 3-6 hrs: n = 6 
Scale bar: 25 m 
GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer 
plexiform layer; ONL: outer nuclear layer; RPE: retinal pigmented epithelium; Ch: choroid. 
 
Figure 5. Effect of subconjunctival injection of 48/80 on choroidal thickness. 
Choroidal thickness was measured on photographs taken on historesin sections from the optic 
nerve to the ciliary body.   
A, B. At 1 hr and 3 hrs after injection of 48/80, choroids from eyes injected with 48/80 (n = 6) 
showed a localized significant increase of thickness compared to contralateral eyes (n = 6) 
and NaCl-injected eyes (n =5). C, D. At 6 hrs and 24 hrs, a significant and extended increase 
of choroidal thickness was shown in choroids from rats injected with 48/80 (n = 6) compared 
to contralateral eyes (n = 6) and NaCL-injected eyes (n = 6).  
 
Figure 6. Effects of mast degranulation on RPE cell jonctions by subconjunctival 
injection of 48/80.  
A-D: RPE flat mounts immunostained with occludin (green) and DAPI (blue) after injection 
of 48/80 or NaCl. In NaCl controls, occludin labeled the regular hexagonal membrane of RPE 
cells (A), whereas 1 hr after injection of 48/80, enlarged RPE cells were seen (B, C, stars) 
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with irrregular occludin labeling originating from loss of junctions between some RPE cells 
(D, arrowhead).  48/80-injected eyes: n = 6; NaCl-injected eyes: n = 5 
E-G: On corresponding historesin sections, in controls, RPE cells were regularly distributed 
between the photoreceptor cells and the choroid (E, arrows). In contrast, after injection of 
48/80, RPE cells were altered or missing (F, asterisk). In some wide places, RPE cells were 
separated from one to another, showed a round shape and were detached from the basal 
membrane (G, white arrows) in front of a retinal detachment area. 
Photomicrographs are representative of similar sections stained from 3 rats per each time 
point. Scale bar: 25 m 
 
Figure 7. Time course of intra-ocular cytokine and chemokine concentrations after 
subconjunctival injection of 48/80.  
TNF- was increased at 1 hr and 3 hrs after 48/80 injection as compared to NaCl-injected 
eyes (A). A significant upregulation of IL-5 at 3 hrs, 6 hrs and 24 hrs was found in 48/80-
injected eye (B), together with an upregulation of IL-6 and CCL-2 at 6 hrs and 24 hrs (C, D) 
as compared to NaCl-injected-eyes. An increase of IL-1 and CXCL-1 (E, F) was detected at 
24 hrs. A significant increase of IL-18 (G) and a significant decrease of VEGF (I) occurred at 
24 hrs in 48/80-injected eyes. The course of levels of IL-18 (H) and VEGF (J) in 48/80-
injected eyes was opposite. At 3 hrs, IL-18 significantly decreased compared to its levels at 1 
hr, whereas VEGF significantly increased compared to its levels at 1 hr. In contrast compared 
to levels at 3 hrs, at 6 hrs and 24 hrs IL-18 significantly increased whereas VEGF 
significantly decreased. 
48/80-injected eyes: n = 4-6 per time point; NaCl-injected eyes (control) : n = 5-6 per time 
point  
 
 
